Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTMX NASDAQ:EDIT NASDAQ:RYTM NASDAQ:SRPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTMXCytomX Therapeutics$3.27-1.1%$2.59$0.40▼$3.91$538.43M2.273.34 million shs1.23 million shsEDITEditas Medicine$3.79+3.7%$3.17$0.91▼$4.54$341.07M2.182.82 million shs1.22 million shsRYTMRhythm Pharmaceuticals$110.53+1.3%$101.29$45.90▼$113.91$7.34B2.12648,745 shs174,703 shsSRPTSarepta Therapeutics$23.08+5.4%$19.88$10.41▼$138.81$2.25B0.516.25 million shs2.61 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTMXCytomX Therapeutics-2.65%+0.61%+56.40%+37.50%+205.56%EDITEditas Medicine+2.24%-7.83%+21.26%+15.87%+13.71%RYTMRhythm Pharmaceuticals-0.05%-1.85%+10.56%+26.22%+122.60%SRPTSarepta Therapeutics-2.58%-6.21%+22.09%+83.49%-83.15%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTMXCytomX Therapeutics$3.27-1.1%$2.59$0.40▼$3.91$538.43M2.273.34 million shs1.23 million shsEDITEditas Medicine$3.79+3.7%$3.17$0.91▼$4.54$341.07M2.182.82 million shs1.22 million shsRYTMRhythm Pharmaceuticals$110.53+1.3%$101.29$45.90▼$113.91$7.34B2.12648,745 shs174,703 shsSRPTSarepta Therapeutics$23.08+5.4%$19.88$10.41▼$138.81$2.25B0.516.25 million shs2.61 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTMXCytomX Therapeutics-2.65%+0.61%+56.40%+37.50%+205.56%EDITEditas Medicine+2.24%-7.83%+21.26%+15.87%+13.71%RYTMRhythm Pharmaceuticals-0.05%-1.85%+10.56%+26.22%+122.60%SRPTSarepta Therapeutics-2.58%-6.21%+22.09%+83.49%-83.15%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTMXCytomX Therapeutics 2.86Moderate Buy$5.8378.66% UpsideEDITEditas Medicine 2.14Hold$5.1034.74% UpsideRYTMRhythm Pharmaceuticals 2.94Moderate Buy$107.21-3.00% DownsideSRPTSarepta Therapeutics 2.03Hold$34.4649.33% UpsideCurrent Analyst Ratings BreakdownLatest SRPT, CTMX, EDIT, and RYTM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/24/2025CTMXCytomX TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)10/24/2025EDITEditas MedicineWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/22/2025SRPTSarepta TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetUnderperform$16.00 ➝ $18.0010/21/2025CTMXCytomX TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$3.50 ➝ $6.0010/17/2025RYTMRhythm PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$157.00 ➝ $139.0010/16/2025RYTMRhythm PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$122.00 ➝ $129.0010/14/2025SRPTSarepta TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025CTMXCytomX TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)10/8/2025EDITEditas MedicineWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025RYTMRhythm PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025SRPTSarepta TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$14.00 ➝ $16.00(Data available from 10/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTMXCytomX Therapeutics$138.10M3.90$0.35 per share9.37($0.01) per share-326.50EDITEditas Medicine$32.31M10.53N/AN/A$1.63 per share2.32RYTMRhythm Pharmaceuticals$130.13M56.41N/AN/A$0.35 per share315.79SRPTSarepta Therapeutics$2.48B0.91$2.50 per share9.22$15.99 per share1.44Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTMXCytomX Therapeutics$31.87M$0.565.83N/AN/A34.04%158.70%36.04%11/6/2025 (Estimated)EDITEditas Medicine-$237.09M-$2.85N/AN/AN/A-608.88%-200.25%-68.57%11/3/2025 (Estimated)RYTMRhythm Pharmaceuticals-$260.60M-$3.01N/AN/AN/A-117.13%-1,831.43%-48.33%11/4/2025 (Estimated)SRPTSarepta Therapeutics$235.24M-$0.87N/A2.11N/A-2.34%-1.03%-0.37%11/5/2025 (Estimated)Latest SRPT, CTMX, EDIT, and RYTM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025CTMXCytomX Therapeutics-$0.04N/AN/AN/A$11.50 millionN/A11/5/2025Q3 2025SRPTSarepta Therapeutics$0.02N/AN/AN/A$331.51 millionN/A11/4/2025Q3 2025RYTMRhythm Pharmaceuticals-$0.72N/AN/AN/A$50.71 millionN/A11/3/2025Q3 2025EDITEditas Medicine-$0.38N/AN/AN/AN/AN/A8/12/2025Q2 2025EDITEditas Medicine-$0.41-$0.63-$0.22-$0.63$1.81 million$3.58 million8/6/2025Q2 2025SRPTSarepta Therapeutics$0.89$2.02+$1.13$1.89$530.66 million$611.09 million8/5/2025Q2 2025RYTMRhythm Pharmaceuticals-$0.66-$0.75-$0.09-$0.75$43.72 million$48.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTMXCytomX TherapeuticsN/AN/AN/AN/AN/AEDITEditas MedicineN/AN/AN/AN/AN/ARYTMRhythm PharmaceuticalsN/AN/AN/AN/AN/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTMXCytomX TherapeuticsN/A4.204.20EDITEditas MedicineN/A2.772.77RYTMRhythm PharmaceuticalsN/A2.792.64SRPTSarepta Therapeutics0.842.891.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTMXCytomX Therapeutics67.77%EDITEditas Medicine71.90%RYTMRhythm PharmaceuticalsN/ASRPTSarepta Therapeutics86.68%Insider OwnershipCompanyInsider OwnershipCTMXCytomX Therapeutics6.60%EDITEditas Medicine2.10%RYTMRhythm Pharmaceuticals6.10%SRPTSarepta Therapeutics7.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTMXCytomX Therapeutics170164.91 million154.03 millionOptionableEDITEditas Medicine23089.92 million88.03 millionOptionableRYTMRhythm Pharmaceuticals14066.42 million62.37 millionOptionableSRPTSarepta Therapeutics1,37297.71 million90.29 millionOptionableSRPT, CTMX, EDIT, and RYTM HeadlinesRecent News About These CompaniesTradr 2X Long SRPT Daily ETF3 hours ago | money.usnews.comTradr Debuts Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULFOctober 23 at 11:20 PM | msn.comSarepta Therapeutics (NASDAQ:SRPT) Price Target Raised to $18.00October 23 at 9:43 AM | marketbeat.comPrivium Fund Management B.V. Makes New $698,000 Investment in Sarepta Therapeutics, Inc. $SRPTOctober 21 at 6:04 AM | marketbeat.comBlair William & Co. IL Sells 16,942 Shares of Sarepta Therapeutics, Inc. $SRPTOctober 18, 2025 | marketbeat.comSarepta Therapeutics, Inc. $SRPT Shares Bought by Janney Montgomery Scott LLCOctober 18, 2025 | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Trading Up 7% - Here's What HappenedOctober 17, 2025 | marketbeat.comWeiss Ratings Reiterates "Sell (D-)" Rating for Sarepta Therapeutics (NASDAQ:SRPT)October 16, 2025 | americanbankingnews.comSarepta’s Not Done With Gene Therapy Yet as New LGMD Asset Yields Promising DataOctober 15, 2025 | biospace.comBSarepta Therapeutics (NASDAQ:SRPT) Receives Sell (D-) Rating from Weiss RatingsOctober 14, 2025 | marketbeat.comAberdeen Group plc Boosts Stake in Sarepta Therapeutics, Inc. $SRPTOctober 14, 2025 | marketbeat.comInspire Investing LLC Raises Stake in Sarepta Therapeutics, Inc. $SRPTOctober 13, 2025 | marketbeat.comCautious Hold Rating on Sarepta Therapeutics Amid Promising but Inconclusive Sirolimus FindingsOctober 13, 2025 | tipranks.comSarepta Therapeutics: A Discounted Valuation Meets Breakthrough PipelineOctober 10, 2025 | seekingalpha.comSarepta Therapeutics (SRPT) Receives a Hold from Mizuho SecuritiesOctober 10, 2025 | theglobeandmail.comSarepta Therapeutics (SRPT) Receives a Buy from JefferiesOctober 10, 2025 | theglobeandmail.comWhat's Going On Sarepta Stock On Wednesday?October 8, 2025 | benzinga.comSarepta Therapeutics (NASDAQ:SRPT) Shares Gap Up After Analyst UpgradeOctober 8, 2025 | marketbeat.comRoyal Bank Of Canada Boosts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $16.00October 8, 2025 | marketbeat.comA Look at Sarepta Therapeutics (SRPT) Valuation Following Recent Share Price GainsOctober 6, 2025 | finance.yahoo.com25,360 Shares in Sarepta Therapeutics, Inc. $SRPT Bought by 111 CapitalOctober 6, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025October’s Top 5 Stocks Poised for Big BreakoutsBy Thomas Hughes | October 1, 2025FICO’s Big Dip Could Be the Best Buying Chance of the YearBy Gabriel Osorio-Mazilli | October 13, 2025Carmakers Step in With Incentives as EV Tax Credit ExpiresBy Jordan Chussler | October 9, 20253 High-Yield Banks for Investors to Buy on the DipBy Thomas Hughes | October 20, 2025SRPT, CTMX, EDIT, and RYTM Company DescriptionsCytomX Therapeutics NASDAQ:CTMX$3.26 -0.04 (-1.06%) As of 03:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.Editas Medicine NASDAQ:EDIT$3.78 +0.14 (+3.70%) As of 03:32 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Rhythm Pharmaceuticals NASDAQ:RYTM$110.52 +1.41 (+1.29%) As of 03:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Sarepta Therapeutics NASDAQ:SRPT$23.08 +1.19 (+5.41%) As of 03:32 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Capital One Just Flashed a Buy Signal—New Highs Could Be Next Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Is Oracle’s AI Rally Over? Wall Street Thinks ORCL Could Hit $400 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
